In vitro quality of amotosalen-UVA pathogen-inactivated mini-pool plasma prepared from whole blood stored overnight.

Date publication

août 2018

Journal

Vox sanguinis

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GACHET Christian

Tous les auteurs :
Ravanat C, Dupuis A, Marpaux N, Naegelen C, Mourey G, Isola H, Laforêt M, Morel P, Gachet C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30079963

Résumé

Small batch-pooled (mini-pool) whole blood (WB)-derived plasma could be an alternative cost-effective source of therapeutic plasma (TP), but carries an increased risk of transfusion-transmitted infection due to exposure of the recipient to several donors. This risk can be mitigated by inactivation of pathogens susceptible to the amotosalen-UVA (AUVA)-treatment. We evaluated the conservation of coagulation factors in AUVA-plasma prepared from WB stored overnight under routine operating conditions, to determine its therapeutic efficacy. Thrombin generation (TG) by the AUVA-plasma was used to provide an integrated measure of the hemostatic capacity.

Mots clés

hemostasis, pathogen inactivation, plasma, quality control

Référence

Vox Sang.. 2018 Aug 6;: